Molecular adsorbent recirculating system in liver transplantation: Safety and efficacy.
We assessed the safety and clinical efficacy of the Molecular Adsorbent Recirculating System (MARS) in liver failure patients admitted to our intensive care unit (ICU) from May 2000 to February 2006. Of 28 adult patients with bilirubin >15 mg/dL and hepatic encephalopathy (HE) grade > or =2 or hepato-renal syndrome, 22 patients were included in the study, because 6 patients were older than 65 years of age or showed recent alcohol abuse or extrahepatic malignancy. Patients were assigned to 2 groups according to whether MARS therapy was associated with a transplantation procedure: 11 patients received MARS therapy and liver transplantation (OLT group) and 11 patients received MARS therapy alone (non-OLT group). Five of 11 patients in the OLT group were listed for transplantation and 6 patients with graft failure for retransplantation. The patients in the OLT and non-OLT groups were similar in MELD, SOFA, and SAPS scores. All patients were stable and free from complications. MARS significantly reduced bilirubin, bile acids, and blood urea nitrogen (BUN) levels in both groups (P < .05), whereas a significant decrease in ammonia level was observed in the OLT group. Patient survival rates at 3 and 6 months in the OLT group were 91% and 73%, respectively, and in the non-OLT group, 9% and 9%, respectively (P < .001). MARS was safe and well tolerated, improving biochemical parameters, neurological function, and pruritus. In terms of survival, the use of MARS alone was not effective due to the high rate of multiple organ failure. Nevertheless, the association of MARS with a transplant/retransplantation procedure was highly effective.
Gaspari
R
R
Department of Anesthesiology-Intensive Care Unit, Catholic University of Rome, Largo A Gemelli, Rome, Italy. atypga@tin.it
Avolio
A W
AW
Zileri Dal Verme
L
L
Agnes
S
S
Proietti
R
R
Castagneto
M
M
Gasbarrini
A
A
D000328:Adult; D000368:Aged; D006801:Humans; D007163:Immunosorbent Techniques; D017093:Liver Failure / Q000401:mortality / Q000628:therapy*; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology*; D008875:Middle Aged; D011183:Postoperative Complications / Q000628:therapy; D015203:Reproducibility of Results; D012449:Safety; D016019:Survival Analysis; D016896:Treatment Outcome